Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 16/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 14/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 7/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14935267 | 0.78 | MCL1 (0.78) | BCL2MCL1BCL2L1 | |
| SCHEMBL14935268 | 0.78 | MCL1 (0.78) | BCL2MCL1BCL2L1 | |
| SCHEMBL12604898 | 0.75 | BCL2 (0.67) | BCL2MCL1BCL2L1 | |
| SCHEMBL14949187 | 0.74 | MCL1 (0.44) | BCL2MCL1BCL2L1 | |
| SCHEMBL14952368 | 0.73 | MCL1 (0.47) | BCL2MCL1BCL2L1 | |
| SCHEMBL11346047 | 0.67 | BCL2 (0.60) | BCL2MCL1BCL2L1PLK1 | |
| SCHEMBL11137447 | 0.67 | MAPT (0.50) | BCL2 | |
| SCHEMBL17617828 | 0.67 | MCL1 (0.52) | BCL2MCL1BCL2L1 | |
| SCHEMBL11674909 | 0.66 | BCL2 (0.59) | BCL2MCL1BCL2L1PLK1 | |
| SCHEMBL21501553 | 0.66 | BCL2 (0.62) | BCL2MCL1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614333-B2 | Acenaphtho heterocyclic compound and application thereof | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-12-24 | — | — | US | disclosed |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123492-A1 | ACENAPHTHO HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | MCL1, BCL2L1, BCL2 | BCL2 3/4885MCL1 1/4885BCL2L1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.